Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 94, Issue 1, Pages 133-143
Publisher
Wiley
Online
2018-10-05
DOI
10.1002/ajh.25303
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mayo CALR mutation type classification guide using alpha helix propensity
- (2018) Terra L. Lasho et al. AMERICAN JOURNAL OF HEMATOLOGY
- JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2 V617F mutated disease
- (2018) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
- (2018) Tiziano Barbui et al. Blood Cancer Journal
- Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger
- (2018) Natasha Szuber et al. AMERICAN JOURNAL OF HEMATOLOGY
- Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
- (2016) Yoseph C. Elala et al. AMERICAN JOURNAL OF HEMATOLOGY
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Myeloproliferative neoplasms: A decade of discoveries and treatment advances
- (2015) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloproliferative Neoplasms
- (2015) Ayalew Tefferi et al. JAMA Oncology
- Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
- (2014) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
- (2014) Alberto Alvarez-Larrán et al. ANNALS OF HEMATOLOGY
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
- (2014) Bruno Cassinat et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
- (2013) H. Gisslinger et al. BLOOD
- JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
- (2013) E. T. Kuriakose et al. HAEMATOLOGICA
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
- (2012) S. Pascale et al. BLOOD
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
- (2012) T. Barbui et al. BLOOD
- A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
- (2012) F. Passamonti et al. BLOOD
- GermlineJAK2Mutation in a Family with Hereditary Thrombocytosis
- (2012) Adam J. Mead et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
- (2011) A. Carobbio et al. BLOOD
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
- (2011) Jean-Jacques Kiladjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count
- (2010) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria
- (2010) A. Carobbio et al. BLOOD
- Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
- (2010) A. Alvarez-Larran et al. BLOOD
- Clinical utility of routineMPLexon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis
- (2010) Elaine M. Boyd et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
- (2010) F Passamonti et al. LEUKEMIA
- The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
- (2009) E. Voskaridou et al. BLOOD
- Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies
- (2009) Naseema Gangat et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia
- (2009) K. Liu et al. HAEMATOLOGICA
- Two rare MPL gene mutations in patients with essential thrombocythemia
- (2009) Haruhiko Ohashi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies
- (2009) F. PASSAMONTI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
- (2008) A. M. Vannucchi et al. BLOOD
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
- (2008) P. A. Beer et al. BLOOD
- Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis
- (2008) Andrew J K Östör CLINICAL RHEUMATOLOGY
- The Role of Clopidogrel and Acetylsalicylic Acid in the Prevention of Early-Phase Graft Occlusion Due to Reactive Thrombocytosis after Coronary Artery Bypass Operation
- (2008) Ilyas Kayacioglu et al. HEART SURGERY FORUM
- Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
- (2008) A M Vannucchi et al. LEUKEMIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started